Pfizer Positions PF-07307405 For Europe First, As U.S. Lyme Discussions Continue

Pfizer said its Valneva-partnered Lyme disease vaccine PF-07307405 is nearing a regulatory submission, but Europe is likely to be the first launch market rather than the U.S. On a third quarter earnings call, executives said discussions with the FDA are still ongoing while the European review is already underway.

The sequencing matters because it shows commercialization strategy following regulatory readiness and existing infrastructure, not just disease visibility. Pfizer executives stressed that the U.S. remains an important market, particularly as awareness and incidence rise, but Europe currently appears to offer the clearer near-term path.

The Regulatory Path

Pfizer confirmed that it is in discussions with the FDA about a regulatory submission for PF-07307405. Chris Boshoff, Pfizer’s chief scientific officer and president of R&D, said an update on those U.S. regulatory discussions will come sometime this quarter. BioSpace reported that analysts have suggested the FDA filing could be completed by the end of the year.

In Europe, the process is further along. Executives said regulators there have commenced their review after the European Medicines Agency confirmed receipt of Pfizer’s application in August. The Committee for Medicinal Products for Human Use is set to deliver its verdict in 2027.

Why Europe Comes First

CEO Albert Bourla said awareness of Lyme disease in the U.S. is “skyrocketing right now” because of increased severity and incidence. Even so, Chief International Commercial Officer Alexandre de Germay said Europe is a natural starting point because Pfizer already owns a tick-borne encephalitis vaccine portfolio marketed there from a long-ago acquisition.

That existing setup gives Pfizer more than regulatory momentum. De Germay said the company already knows how to activate tick-borne populations in endemic areas because it has a sales force and a commercial play with pharmacies. He added that Lyme is much more known than tick-borne encephalitis, which should help with commercialization.

The signal for industry is that vaccine launch order can be shaped as much by channel readiness as by disease burden. Pfizer appears to be using an established regional commercial base to lower execution risk for a product category that depends heavily on targeted awareness in endemic areas.